Deutsche Bank lowered shares of ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) from a buy rating to a hold rating in a research note released on Thursday, The Fly reports.

Separately, Goldman Sachs Group lowered ASTELLAS PHARMA/ADR from a buy rating to a neutral rating in a research report on Friday, June 8th.

OTCMKTS:ALPMY opened at $16.95 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.93 and a quick ratio of 1.59. ASTELLAS PHARMA/ADR has a 1-year low of $12.34 and a 1-year high of $17.28. The firm has a market capitalization of $33.50 billion, a P/E ratio of 21.97 and a beta of 0.37.

ASTELLAS PHARMA/ADR Company Profile

Astellas Pharma Inc, a pharmaceutical company, manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, an immunosuppressant used to suppress organ transplant rejection; Vesicare, a treatment for overactive bladder; Harnal/Omnic, a blocking agent to treat the functional symptoms of benign prostatic hyperplasia; and Funguard/MYCAMIN, a candin-type antifungal agent.

Featured Story: The Role of a Fiduciary and Individual Investors

The Fly

Receive News & Ratings for ASTELLAS PHARMA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASTELLAS PHARMA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.